INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life SciencePRNewsWire · 4 days ago
Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)Defense World · Oct 1, 2026
Bet on 4 Top-Ranked Stocks With Rising P/EZacks Investment Research · Sep 14, 2026
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks TranscriptSeeking Alpha · Sep 11, 2026
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date LoomsMarketBeat · Sep 11, 2026
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRPMarketBeat · Sep 10, 2026Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.22 | -$0.07 | Beat |
| May 13, 2026 | -$0.35 | -$0.28 | Beat |
| Mar 12, 2026 | -$0.37 | $0.06 | Beat |
| Nov 10, 2025 | -$0.42 | -$0.87 | Miss |
| Aug 12, 2025 | -$0.63 | -$0.61 | Beat |
| May 13, 2025 | -$0.74 | -$0.51 | Beat |